<< Back to News

FDA Approves Genentech's RITUXAN HYCELA™

On June 22, 2017, RITUXAN HYCELA™(rituximab/hyaluronidase human) was approved by the US Food and Drug Administration (FDA). 

Genentech Access Solutions offers a full range of access and reimbursement support to help you and your patients understand their coverage and get assistance with out-of-pocket (OOP) costs so treatment can begin as soon as possible. 

Genentech Access Solutions can help your patients and practice address each patient’s coverage scenario: 

  • Full benefits investigations to verify coverage
  • Prior authorization resources
  • Sample billing and coding information
  • Resources for appeals
  • Co-pay assistance option identification to help eligible insured patients with OOP costs
  • Free medicine for qualified uninsured and underinsured patients through the Genentech® Access to Care Foundation 

Click Here for billing and coding information on RITUXAN HYCELA 

Click the link below for full Prescribing Information and additional Important Safety Information: https://www.gene.com/download/pdf/rituxan_hycela_prescribing.pdf.